RNS Number : 9347N
Advanced Medical Solutions Grp PLC
23 June 2025
23 June 2025
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Directorate Change
Juliet Thompson to be Appointed as an Independent Non-Executive Director
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, is pleased to announce that our search for an additional Independent Non-Executive Director has successfully concluded and that Juliet Thompson will be appointed as a Non-Executive Director and Chair of the Audit Committee following the conclusion of the AGM on 30 June.
Juliet has over 30 years of finance, banking and board experience with significant focus in the healthcare sector. She is a proven FTSE 250 Audit Committee Chair and a former investment banker who has spent her career advising pharmaceutical and medtech companies. She played a leading role in setting up Code Securities, which was later acquired by Nomura (becoming Nomura Code) but remained independent. At Nomura Code, Juliet advised companies in the healthcare and clean tech sectors on their financing and strategic options. She worked on over 50 transactions including IPOs, secondary offerings, private placements and M&A. As Nomura Code was devolved, she joined Stifel with a team from Nomura Code to head up the life sciences team where she advised CEOs and CFOs in the healthcare sector. She was Audit Committee Chair at Vectura Group Limited.
Juliet has built a diverse portfolio; she is currently a Non-Executive Director and Chair of the Audit Committees of: Indivior plc, a NASDAQ listed company working to develop medicines to treat addiction; Novacyt S.A., a Euronext and AIM listed diagnostic company; and Organox Limited, a private company spun out of Oxford University developing innovative solutions for organ preservation prior to transplantation. Juliet holds a BSc in Economics from the University of Bristol and qualified as a Chartered Accountant and holds an ACA from the Association of Chartered Certified Accountants.
Grahame Cook, Chair of AMS, said: "I am very pleased to welcome Juliet to the Board of AMS. She has a wealth of Board experience, particularly focused on healthcare companies, and is a proven Audit Committee Chair. She will be a valuable addition to our Board."
Juliet Thompson commented: "I have followed AMS progress over the last few years and am excited to be joining the Board as the company continues its growth journey."
Juliet will immediately be appointed as Chair of the Audit Committee and join the Nomination and Remuneration Committees. The composition of each of the Board Committees from 30 June 2025 is therefore confirmed as follows:
Board Committee
Membership
Audit Committee
Juliet Thompson (Chair) Grahame Cook Douglas Le Fort Susan Searle
Nomination Committee
Grahame Cook (Chair) Douglas Le Fort Susan Searle Juliet Thompson
Remuneration Committee
Douglas Le Fort (Chair) Grahame Cook Susan Searle Juliet Thompson
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
Juliet Thompson (aged 59 years) holds or has held Directorships and partnerships in the five years preceding her appointment at AMS as follows:
Current Directorships
Previous Directorships
Indivior plc
Angle plc
OrganOx Ltd
Leadership Through Sport and Business
NovacytGroup
Opus 107 Limited
Opus Trust Investments Limited
Vectura Group Limited
GI Dynamics, Inc
No further information in connection with her appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.
- End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc
Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations
ICR Healthcare
Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott/ Lucy Featherstone
AMS@icrhealthcare.com
Investec Bank PLC (NOMAD & Broker)
Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson
Berenberg (Joint Broker)
Tel: +44 (0)20 3207 7800
Toby Flaux / Detlir Elezi / Yasmina Benchekroun
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,600 employees. For more information, please see www.admedsol.com.
-
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAPPUUCQUPAUAW
